CN102858156B - 用于提供治疗的方法、组合物和试剂盒 - Google Patents

用于提供治疗的方法、组合物和试剂盒 Download PDF

Info

Publication number
CN102858156B
CN102858156B CN201180020423.4A CN201180020423A CN102858156B CN 102858156 B CN102858156 B CN 102858156B CN 201180020423 A CN201180020423 A CN 201180020423A CN 102858156 B CN102858156 B CN 102858156B
Authority
CN
China
Prior art keywords
cancer
therapy
treatment
day
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180020423.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102858156A (zh
Inventor
奥斯娜特·阿舒尔-费边
亚力克·海尔克博格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102858156A publication Critical patent/CN102858156A/zh
Application granted granted Critical
Publication of CN102858156B publication Critical patent/CN102858156B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180020423.4A 2010-04-28 2011-04-28 用于提供治疗的方法、组合物和试剂盒 Expired - Fee Related CN102858156B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32882510P 2010-04-28 2010-04-28
US61/328,825 2010-04-28
PCT/IL2011/000346 WO2011135574A1 (en) 2010-04-28 2011-04-28 Methods, compositions and kits for providing a therapeutic treatment

Publications (2)

Publication Number Publication Date
CN102858156A CN102858156A (zh) 2013-01-02
CN102858156B true CN102858156B (zh) 2015-09-23

Family

ID=44860959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180020423.4A Expired - Fee Related CN102858156B (zh) 2010-04-28 2011-04-28 用于提供治疗的方法、组合物和试剂盒

Country Status (11)

Country Link
US (2) US9655984B2 (enExample)
EP (1) EP2563120B1 (enExample)
JP (1) JP5921529B2 (enExample)
KR (1) KR101841304B1 (enExample)
CN (1) CN102858156B (enExample)
AU (1) AU2011246851B2 (enExample)
BR (1) BR112012027463A2 (enExample)
CA (1) CA2797625C (enExample)
ES (1) ES2791708T3 (enExample)
MX (1) MX2012012479A (enExample)
WO (1) WO2011135574A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386702B (es) 2014-02-10 2025-03-19 Fred Hutchinson Cancer Center Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CN105486869A (zh) * 2014-10-08 2016-04-13 江苏维赛科技生物发展有限公司 一种检测动物源食品中甲巯咪唑残留的酶联免疫试剂盒及其应用
US20200222348A1 (en) * 2017-05-08 2020-07-16 Musli Thyropeutics Ltd. Bimodal modified release compositions for cancer treatment
WO2021257806A1 (en) * 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome
CN114605278A (zh) * 2022-02-11 2022-06-10 天津市肿瘤医院（天津医科大学肿瘤医院） T3或其可药用盐在制备脑胶质瘤放化疗药物方面的应用
CN114878840A (zh) * 2022-07-12 2022-08-09 昆明思安生物科技有限公司 磁微粒化学发光测定三碘甲状腺原氨酸试剂盒及检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB851610A (en) 1956-03-07 1960-10-19 Gunther Hillman Method for producing iodine derivatives of thyronine
US4426453A (en) 1980-09-18 1984-01-17 Amersham International Limited Derivatives of iodothyronine compounds and their use in an assay for the free iodothyronine compounds
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US6017958A (en) 1996-06-04 2000-01-25 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US6939863B2 (en) * 2002-01-04 2005-09-06 Wei-Jan Chen Prevention of atherosclerosis and restenosis
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
JP2009507847A (ja) * 2005-09-08 2009-02-26 シャイア エルエルシー 生体利用性を増強したｔ３及びｔ４のプロドラッグ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Thyroid and Bone;Jason A. Wexler et al;《Endocrinol Metab Clin N Am》;20071231(第36期);673-705 *

Also Published As

Publication number Publication date
AU2011246851A1 (en) 2012-11-15
MX2012012479A (es) 2013-07-03
EP2563120A4 (en) 2015-05-13
BR112012027463A2 (pt) 2015-09-29
EP2563120A1 (en) 2013-03-06
US20170274104A1 (en) 2017-09-28
EP2563120B1 (en) 2020-02-26
JP5921529B2 (ja) 2016-05-24
CA2797625A1 (en) 2011-11-03
US10398789B2 (en) 2019-09-03
AU2011246851B2 (en) 2016-07-21
KR20130103336A (ko) 2013-09-23
JP2013525422A (ja) 2013-06-20
US9655984B2 (en) 2017-05-23
ES2791708T3 (es) 2020-11-05
US20130129615A1 (en) 2013-05-23
CA2797625C (en) 2019-08-20
WO2011135574A1 (en) 2011-11-03
KR101841304B1 (ko) 2018-03-22
CN102858156A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
CN102858156B (zh) 用于提供治疗的方法、组合物和试剂盒
JP5677296B2 (ja) グリオーマの治療のためのｃｄｋ阻害剤の使用
CN104327141B (zh) Rna纳米颗粒及其在胃癌防治中的应用
US10183035B2 (en) Etoposide and prodrugs thereof for use in targeting cancer stem cells
KR102615210B1 (ko) 난소암의 치료에 사용되는 티노스타무스틴
JP6446134B2 (ja) 癌幹細胞治療用組成物
JP5479453B2 (ja) ＯＮ０１９１０．Ｎａは薬剤耐性腫瘍において化学療法剤活性を増強する
JPWO2015178426A1 (ja) がん幹細胞の増殖抑制剤
US10751352B2 (en) Pharmaceutical composition for preventing or treating cancer
CN106860460A (zh) 谷氨酰胺酶抑制剂cb‑839在制备治疗雌激素敏感型子宫内膜癌的药物中的应用
RU2706341C1 (ru) Способ лечения неоперабельной аденокарциномы головки поджелудочной железы
WO2018053270A1 (en) Modified natural killer cells for the treatment of cancer
WO2019138203A1 (fr) Composition comprenant l'hydroxychloroquine et utilisation therapeutique
US20250302918A1 (en) Methods and compositions relating to treatment of cns diseases
CN112674028B (zh) 促诱癌剂诱发动物癌症模型建立的方法
CN107715103A (zh) Clusterin在制备杀伤肿瘤干细胞的癌症治疗药物中的应用
JP2015003902A (ja) 血管新生阻害剤
CN119421707A (zh) (s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗癌症中的用途
TW201605430A (zh) γ－紅沒藥烯（γ－Ｂｉｓａｂｏｌｅｎｅ）於治療口腔癌之用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150923

Termination date: 20210428